THE PREDICTIVE PATHOLOGY IN THE TARGET THERAPY ERA

Aims & Scope:

The advent and success of molecular targeted therapies has prompted researchers to investigate new potential biomarkers to better define molecular profile and biological characteristics of each single tumor entity. The establishment of complete molecular portrait of oncologic patient will not only allow to sub-classify tumor types from a biological point of view, but also to realize a real personalized medicine. Currently mutational status and/or aberrant expression of certain markers, such as EGFR, HER2, c-KIT, BRAF, ALK, etc, identified in several tumor types, represent molecular targets for new and efficacious biological therapy. However, over the last years, through innovative molecular techniques many other molecular alterations have been characterized and used for targeting therapies. The issue should be structured planning updated reviews on the impact of biomarkers currently used in clinical setting in order to stratify patients therapeutic strategies and reviews and/or original articles on new possible targeting biomarkers.

Key words: predictive pathology, target therapy, biomarkers, molecular pathology, prognosis

Subtopics:

Predictive pathology in Breast cancer
Predictive pathology in Lung Cancer
Predictive pathology in Melanoma
Predictive pathology in Colo-Rectal cancer
New predictive Biomarkers for Haematological and solid tumors

Schedule:

Manuscript submission deadline: August 2014
Peer Review Due: September 2014
Revision Due: October 2014
Notification of acceptance by the Guest Editor: November 2014
Final manuscripts due: November 2014